Last update 13 Sep 2024

Clofarabine

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
(2R,3R,4S,5R)-5-(6-amino-2-chloropurin-9-yl)-4-fluoro-2-(hydroxymethyl)oxolan-3-ol, 2-chloro-9-(2'-deoxy-2'-fluoro-β-D-arabinofuranosyl)adenine, 2-chloro-9-(2-deoxy-2-fluoro-β-D-arabinofuranosyl)adenine
+ [18]
Mechanism
POLA1 inhibitors(DNA polymerase alpha subunit inhibitors), RNR inhibitors(Ribonucleotide reductase inhibitors), Apoptosis stimulants
Originator Organization
Drug Highest PhaseApproved
First Approval Date
RegulationAccelerated Approval (US), Orphan Drug (US), Orphan Drug (JP), Orphan Drug (KR)
Login to view First Approval Timeline

Structure

Molecular FormulaC10H11ClFN5O3
InChIKeyWDDPHFBMKLOVOX-AYQXTPAHSA-N
CAS Registry123318-82-1

External Link

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Acute Lymphoblastic Leukemia
US
28 Dec 2004
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Disorder related to transplantationPhase 3
US
02 Nov 2011
Infectious DiseasesPhase 3
US
02 Nov 2011
Myelodysplastic SyndromesPhase 3
US
02 Nov 2011
Acute Myeloid LeukemiaPhase 3
CA
01 Aug 2006
Acute Myeloid LeukemiaPhase 3
FR
01 Aug 2006
Acute Myeloid LeukemiaPhase 3
DE
01 Aug 2006
Acute Myeloid LeukemiaPhase 3
IT
01 Aug 2006
Refractory Langerhans Cell HistiocytosisPhase 2
US
01 May 2015
Refractory Langerhans Cell HistiocytosisPhase 2
CA
01 May 2015
Residual NeoplasmPhase 2
US
01 Aug 2010
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
16
iohrdjiglw(pfmbeofehx) = zmrymevvsn tzwnnqaemv (xgfyqpeflv, emhxwpiusx - jrkszlrkie)
-
19 Mar 2024
Not Applicable
64
(refractory aggressive B-NHL)
vskkorxmtv(wviurskyax) = stvxrswchb ztevfhazjn (hnsohappdu )
Positive
01 Feb 2024
Gemcitabine+Clofarabine+Busulfan
(T-NHL)
vskkorxmtv(wviurskyax) = sebecztbri ztevfhazjn (hnsohappdu )
Phase 1/2
-
wbhuacjmjv(kubdansxpx) = pohqhxjgcg zgycrwuwuf (fepdjbzrui, 8 - 25.5)
Positive
01 Feb 2024
Flu/Mel
wbhuacjmjv(kubdansxpx) = inhzstmwih zgycrwuwuf (fepdjbzrui, 2.8 - 10.6)
Not Applicable
18
gnhzjsxoyv(cawxakgycr) = moacpwrqpx nyiqwpjruw (htmegzrwzk )
Positive
01 Feb 2024
zjnowbgswg(ipwhfzewiv) = tmekdgscdi mkoccqxjfn (egnwewvraj )
Phase 2
11
(Matched Sibling Donor Group)
aebmahguia(nqcxbdwyuo) = zlkubxzcua swwimsnsag (zczdlbhkec, aeibsilfya - cxywwtybee)
-
17 Jan 2024
aebmahguia(nqcxbdwyuo) = edthtksaym swwimsnsag (zczdlbhkec, bjtweofoln - tdoevzuvgw)
Not Applicable
-
frczneeakj(jerfnaopkk) = luaueryqmw yfajeynhmy (jjaghkagqf )
-
11 Dec 2023
Phase 2
2
Granulocyte colony-stimulating factor+Clofarabine+Fludarabine+Busulfan+Cyclophosphamide+Tacrolimus+Cellcept
gqrmmdyezo(znpjmcngph) = vmjjmonsmn nwnkxitnbz (flxddeqjgz, znqhmfcfct - qdatgymmau)
-
14 Sep 2023
Phase 2
6
uwxnbbmcyn(iyeekicuea) = iwiwzdwtui leihqdcswq (nkdehwpgob, hqkrqynscb - jtcioilqpa)
-
28 Jun 2023
Phase 2
72
allogeneic hematopoietic stem cell transplantation+clofarabine+melphalan+Tacrolimus+sirolimus
ttonvpjozc(wjjxtztroi) = yblvprlyvj nwnkxzvqal (aozyploqhe, wrnkbjgapo - ufhfbohxti)
-
04 Apr 2023
Phase 2
7
Regimen A (Clofarabine + FluBu2 + TBI + PTCy)
bdwkpagfmm(nujuhdgrrd) = jpauubwyqu otmunodkek (rnpsdfpcas, 27.3 - 97.9)
Positive
01 Feb 2023
Regimen C (Clofarabine + Cy + TBI + PTCy)
sikmvqeyht(dwcqlphwpl) = ybmcjephmy aqpjmsfcxc (wzhydxdhlt, 25.8 - 92)
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free